KR20010018722A - Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate and a process for preparing thereof - Google Patents
Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate and a process for preparing thereof Download PDFInfo
- Publication number
- KR20010018722A KR20010018722A KR1019990034793A KR19990034793A KR20010018722A KR 20010018722 A KR20010018722 A KR 20010018722A KR 1019990034793 A KR1019990034793 A KR 1019990034793A KR 19990034793 A KR19990034793 A KR 19990034793A KR 20010018722 A KR20010018722 A KR 20010018722A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- methyl
- ethyl
- compound
- piperazinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 활성 항균제로서 유용한 약제의 제조시에 중간체로 사용될 수 있는 하기 화학식 1의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트 및 그의 제조방법에 관한 것이다.The present invention is ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl of the formula (1) which can be used as an intermediate in the preparation of a medicament useful as an active antimicrobial agent. -3 (S)-(1-hydroxypropy-2-ylamino) acrylate and a method for producing the same.
상기 화학식 1의 화합물은 광학활성을 갖는 화합물로서, 이 화합물의 라세미체를 제조하는 방법은 한국특허 공개공보 제92-12087호에 개시되어 있다.The compound of Formula 1 is a compound having optical activity, and a method for preparing a racemate of the compound is disclosed in Korean Patent Publication No. 92-12087.
상기 기술에 따르면, 하기 화학식 2의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트를 화학식 12의 디메틸포름아미드 디메틸아세탈 및 라세미체인 화학식 14의 2-아미노-1-프로판올과 반응시켜 화학식 15의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3-(1-히드록시프로피-2-닐아미노)아크릴레이트를 얻을 수 있다.According to the above technique, the ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate of formula (2) is a dimethylformamide dimethylacetal and racemate of formula (12) Is reacted with 2-amino-1-propanol of ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3- (1-hydride) Roxypropy-2-ylamino) acrylate can be obtained.
그러나 상기 반응식 1의 제조방법은 출발물질인 화학식 12의 화합물이 고가이며 수분에 매우 민감하고 톨루엔등 인화성이 강한 용매를 사용하여 반응시키므로 산업적으로 적용하기에 부적절하다는 문제점이 있다.However, the preparation method of Scheme 1 has a problem that the compound of Formula 12, which is a starting material, is expensive and very sensitive to moisture, and reacts with a highly flammable solvent such as toluene, which is inappropriate for industrial application.
본 발명자들은 상기 문제점을 해결하기 위하여 많은 연구와 노력을 한 결과, 보다 간편하고 수득율이 높은 새로운 물질 및 그의 제조방법을 발견하게 되어 본 발명을 완성하였다.The present inventors have made a lot of research and efforts to solve the above problems, and as a result, have found a new material and a method for preparing the same, which is simpler and higher in yield.
본 발명의 목적은 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트 및 그의 제조방법을 제공하는 것이다.An object of the present invention is ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropyn-2-yl Amino) acrylate and its manufacturing method are provided.
본 발명은 하기 화학식 1의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트 및 이를 제조하는 방법에 관한 것이다.The present invention provides ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropy-2) -Nylamino) acrylate and a method for preparing the same.
상기 화학식 1의 화합물의 제조방법을 하기 반응식 2를 들어 설명하면 다음과 같다.The preparation method of the compound of Formula 1 will be described with reference to Scheme 2 below.
상기 반응식 2에서, 상기 화학식 2의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트와 시판중인 상기 화학식 3의 트리에틸 올소포르메이트를 비극성용매하에 반응온도 20~200℃, 바람직하게는 100~120℃에서 2~50시간, 바람직하게는 22~28시간동안 반응시켜 중간체인 상기 화학식 4의 화합물을 제조하고, 이를 광학활성을 갖는 상기 화학식 5의 (S)-(+)-2-아미노-1-프로판올과 극성용매하에 반응온도 0~100℃, 바람직하게는 10~30℃에서 1~10시간, 바람직하게는 2~3시간 반응시켜 목적화합물을 정량적인 높은 수율로 간단하게 제조할 수 있다.In Scheme 2, a non-polar solvent is substituted with ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate of Formula 2 and commercially available triethyl olsoformate of Formula 3 Under the reaction temperature of 20 ~ 200 ℃, preferably 100 ~ 120 ℃ 2 to 50 hours, preferably 22 to 28 hours to prepare a compound of formula (4) as an intermediate, the formula 5 having an optical activity Under reaction of (S)-(+)-2-amino-1-propanol with polar solvent at a reaction temperature of 0 to 100 캜, preferably 10 to 30 캜 for 1 to 10 hours, preferably 2 to 3 hours. Compounds can be prepared simply in quantitative high yields.
한편 상기 화학식 2의 화합물을 비극성용매하에 트리에틸 올소프로메이트와 반응시켜 상기 화학식 4의 화합물을 얻은 후, 이를 분리하지 않고 비극성용매만을 감압제거한 다음 상기 화학식 5의 화합물과 극성용매하에 반응시켜 목적화합물을 얻는 것도 가능하다.Meanwhile, the compound of Formula 2 is reacted with triethyl olsopromate under a non-polar solvent to obtain the compound of Formula 4, and then only the non-polar solvent is removed under reduced pressure without separation, followed by reaction with the compound of Formula 5 under a polar solvent. It is also possible to obtain.
상기 방법에서 사용되는 비극성용매는 톨루엔, 벤젠 및 헥산 등으로 이루어진 군으로부터 선택되는 용매 또는 이들을 2종 이상 혼합하여 얻어지는 혼합용매를 예로 들 수 있다.Examples of the nonpolar solvent used in the above method include a solvent selected from the group consisting of toluene, benzene and hexane, or a mixed solvent obtained by mixing two or more thereof.
상기 방법에서 사용되는 극성용매는 디메틸술폭시드, 디메틸포름아미드, 디메틸아세트아미드, 아세토니트릴, 물 및 에탄올성용매 등으로 이루어진 군으로부터 선택되는 용매 또는 이들을 2종 이상 혼합하여 얻어지는 혼합용매를 예로 들 수 있다.Examples of the polar solvent used in the above method include a solvent selected from the group consisting of dimethyl sulfoxide, dimethylformamide, dimethylacetamide, acetonitrile, water and ethanol solvent, or a mixed solvent obtained by mixing two or more thereof. have.
상기 반응식 2에서, 출발물질로 사용되는 화학식 2의 화합물은 공지의 화합물[참조: Chem. Pharm. Bull., Vol. 34, 4098∼4102 (1986)]로서 하기 반응식 3과 같이 하기 화학식 6의 테트라플루오로벤조일클로라이드로부터 간단히 제조할 수 있다.In Scheme 2, the compound of Formula 2 used as a starting material is a known compound [see Chem. Pharm. Bull., Vol. 34, 4098-4102 (1986)] can be prepared simply from tetrafluorobenzoyl chloride represented by the following formula (6).
또한 상기 반응식 2에서, 광학활성을 갖는 화학식 5의 화합물은 하기 반응식 4와 같이 저렴한 화학식 10의 L-알라닌(L-Alanine)을 환원제를 사용하여 환원시킴으로써 천연으로부터 쉽게 얻을 수 있다.In addition, in Scheme 2, the compound of Formula 5 having optical activity can be easily obtained from nature by reducing L-Alanine of Formula 10, which is inexpensive as in Scheme 4, using a reducing agent.
상기 방법에서 사용되는 환원제는 수소화알루미늄리튬, 삼플루오로붕소, 라니니켈 또는 수소화붕소나트륨 등을 예로 들 수 있다.Reducing agents used in the above method may include lithium aluminum hydride, boron trifluoro, ranickel or sodium borohydride.
상기와 같이 본 발명의 방법으로 제조된 상기 화학식 1의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트는 항균제로 유용한 약제인 하기 화학식 11의 (-)-9-플루오로-2,3-디히드로-3(S)-메틸-10-(4-메틸-1-피페라지닐)-7-옥소-7H-피리도[1,2,3-데]-1,4-벤즈옥사진-6-카르복실산(레보플록사신; Levofloxacin)의 제조시 중간체로 사용할 수 있다.As described above, ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-( 1-hydroxypropy-2-ylamino) acrylate is a (-)-9-fluoro-2,3-dihydro-3 (S) -methyl-10- (4) -Methyl-1-piperazinyl) -7-oxo-7H-pyrido [1,2,3-de] -1,4-benzoxazine-6-carboxylic acid (levofloxacin; Levofloxacin) Can be used as
하기 실시예를 들어 본 발명을 보다 구체적으로 설명하지만, 이들이 본 발명을 제한하는 것은 아니다.The present invention is explained in more detail with reference to the following examples, but these are not limitative of the present invention.
실시예 1 : (S)-(+)-2-아미노-1-프로판올의 제조Example 1: Preparation of (S)-(+)-2-amino-1-propanol
75.9g(2mole)의 수소화알루미늄리튬을 100ml의 테트라히드로푸란에 혼탁시킨 용액을 0℃까지 냉각하고 89.1g(1mole)의 L-알라닌을 서서히 적가한 다음 60℃까지 가열하여 24시간동안 격렬하게 교반시켰다. 반응이 완결되면 0℃까지 냉각하고 360ml의 물 및 90ml의 15% 수산화나트륨수용액을 순차적으로 가하여 맹렬히 교반 후 침전물을 여과하여 제거한다. 이 반응 혼합액을 황산 마그네슘으로 건조하고 감압증류하여 테트라히드로푸란을 제거시켜 61.6g(82%)의 (S)-(+)-2-아미노-1-프로판올을 얻었다.A solution of 75.9 g (2 mole) of lithium aluminum hydride suspended in 100 ml of tetrahydrofuran was cooled to 0 ° C., 89.1 g (1 mole) of L-alanine was slowly added dropwise, and then heated to 60 ° C. and vigorously stirred for 24 hours. I was. After the reaction was completed, the mixture was cooled to 0 ° C., and 360 ml of water and 90 ml of 15% sodium hydroxide solution were sequentially added thereto, followed by vigorous stirring to remove the precipitate by filtration. The reaction mixture was dried over magnesium sulfate and distilled under reduced pressure to remove tetrahydrofuran to give 61.6 g (82%) of (S)-(+)-2-amino-1-propanol.
IR: υmax(cm-1): 3,345, 3,307, 3,160, 1,621, 1,593IR: υ max (cm -1 ): 3,345, 3,307, 3,160, 1,621, 1,593
H1NMR(CDCl3, 300MHz)(ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):
1.03 (3H, d, =CHCH3), 2.79 (1H, m, -OH),1.03 (3H, d, = CHCH 3 ), 2.79 (1H, m, -OH),
2.98 (1H, m, =CHCH3), 3.23 (2H, t, -NH2),2.98 (1H, m, = CHCH 3 ), 3.23 (2H, t, -NH 2 ),
3.51 (2H, d, -CH2OH)3.51 (2H, d, -CH 2 OH)
[α]D= +18°(c=1.8, H2O)[α] D = + 18 ° (c = 1.8, H 2 O)
실시예 2: 에틸 2,3,4,5-테트라플루오로벤조일아세테이트의 제조Example 2: Preparation of ethyl 2,3,4,5-tetrafluorobenzoyl acetate
357.4g(2.1mole)의 디에틸말로네이트 칼륨염, 238.1g(2.5mole)의 마그네슘클로라이드와 222.6g(2.2mole)의 트리에틸아민을 5,000ml의 아세토니트릴에 혼탁시킨 용액을 10℃까지 냉각하여 2시간 교반하고, 여기에 212.6g(1mole)의 테트로플루오로벤조일클로라이드를 서서히 적가한 다음 상온에서 24시간 격렬하게 교반시켰다. 반응이 완결되면 감압증류하여 아세토니트릴을 제거하고 1,500ml의 톨루엔 및 1,500ml의 2N-염산수용액을 주입하여 맹렬히 교반 후 2N-수산화나트륨수용액으로 중화한 다음 유기층을 분리하였다. 이 반응혼합액을 황산마그네슘으로 건조하고 감압증류하여 용매를 제거한 후 잔사를 헵탄으로 결정화하여 미황색의 에틸 2,3,4,5-테트라플루오로벤조일아세테이트 256.3g(94%)을 얻었다.357.4 g (2.1 mole) diethylmalonate potassium salt, 238.1 g (2.5 mole) magnesium chloride and 222.6 g (2.2 mole) triethylamine were suspended in 5,000 ml of acetonitrile. After stirring for 2 hours, 212.6 g (1 mole) of tetrafluorobenzoyl chloride was slowly added dropwise thereto, followed by vigorous stirring at room temperature for 24 hours. After the reaction was completed, the mixture was distilled under reduced pressure to remove acetonitrile, 1,500 ml of toluene and 1,500 ml of 2N hydrochloric acid solution were injected, stirred vigorously, neutralized with 2N-sodium hydroxide aqueous solution, and the organic layer was separated. The reaction mixture was dried over magnesium sulfate, distilled under reduced pressure to remove the solvent, and the residue was crystallized with heptane to give 256.3 g (94%) of pale yellow ethyl 2,3,4,5-tetrafluorobenzoyl acetate.
융점: 63∼64℃ (dec.)Melting Point: 63 ~ 64 ℃ (dec.)
IR: υmax(cm-1): 1,735, 1,644, 1,615IR: υ max (cm -1 ): 1,735, 1,644, 1,615
H1NMR (CDCl3, 300MHz)(ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):
1.31 (3H, m, -OCH2CH3), [3.96(d), 5.84(s), 12.71(s)] (2H, -CH2-),1.31 (3H, m, -OCH 2 CH 3 ), [3.96 (d), 5.84 (s), 12.71 (s)] (2H, -CH 2- ),
4.26 (2H, m, -OCH2CH3), 7.56 (1H, 방향성 H)4.26 (2H, m, -OCH 2 CH 3 ), 7.56 (1H, aromatic H)
실시예 3: 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트의 제조Example 3: Preparation of ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate
264.2g(1mole)의 에틸 2,3,4,5-테트라플루오로벤조일아세테이트, 150.3g (1.5mole)의 4-메틸-피페라진 및 84.01g(1.5mole)의 중탄산나트륨을 2,000ml의 아세토니트릴에 혼탁시킨 용액을 90℃까지 가열하여 3시간 동안 격렬하게 교반시켰다. 반응이 완결되면 감압증류하여 아세트니트릴을 제거하고 1,000ml의 물 및 1,000ml의 클로로포름을 주입하여 맹렬히 교반 후 클로로포름층을 분리한 다음 동량의 물로 세척하였다. 이 반응혼합액을 황산마그네슘으로 건조하고 감압증류하여 용매를 제거한 후 잔사를 헥산으로 결정화하여 미황색의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트 316.8g(92%)을 얻었다.2,000 ml of acetonitrile in 264.2 g (1 mole) ethyl 2,3,4,5-tetrafluorobenzoyl acetate, 150.3 g (1.5 mole) 4-methyl-piperazine and 84.01 g (1.5 mole) sodium bicarbonate The solution that was clouded on was heated to 90 ° C. and vigorously stirred for 3 hours. After completion of the reaction, distillation under reduced pressure was carried out to remove acetonitrile, 1,000 ml of water and 1,000 ml of chloroform were injected thereto, followed by vigorous stirring to separate the chloroform layer, followed by washing with the same amount of water. The reaction mixture was dried over magnesium sulfate, distilled under reduced pressure to remove the solvent, and the residue was crystallized from hexane to give a slightly yellow ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate. 316.8 g (92%) were obtained.
융점: 60∼61℃ (dec.)Melting Point: 60 ~ 61 ℃ (dec.)
IR: υmax(cm-1) : 1,746, 1,673, 1,620IR: υ max (cm -1 ): 1,746, 1,673, 1,620
H1NMR (CDCl3, 300MHz)(ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):
1.27 and 1.33 (3H, m, -OCH2CH3), 2.34 (3H, s, =NCH3),1.27 and 1.33 (3H, m, -OCH 2 CH 3 ), 2.34 (3H, s, = NCH 3 ),
2.49∼2.57 (4H, m, 피페라진 H), 3.32∼3.44 (4H, m, 피페라진 H),2.49 to 2.57 (4H, m, piperazine H), 3.32 to 3.44 (4H, m, piperazine H),
[3.91(d), 5.78(s), 12.64(s)] (2H, -CH2-),[3.91 (d), 5.78 (s), 12.64 (s)] (2H, -CH 2- ),
4.22 and 4.26 (2H, each q, -OCH2CH3), 7.29∼7.36 (1H, 방향성 H)4.22 and 4.26 (2H, each q, -OCH 2 CH 3 ), 7.29-7.36 (1H, aromatic H)
실시예 4: 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일아크릴레이트의 제조Example 4: Preparation of ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoylacrylate
344.3g(1mole)의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트와 296.4g(2mole)의 트리에틸올소포르메이트를 2,000ml의 툴루엔에 녹인 용액을 110℃까지 가열하여 24시간 동안 교반시켰다. 반응이 완결되면 1,000ml의 물을 가하여 맹렬히 교반 후 톨루엔층을 분리하고, 다시 동량의 물로 세척하였다. 이 반응혼합액을 황산마그네슘으로 건조하고 감압증류하여 용매를 제거하여 323.5g(99%)의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일아크릴레이트를 얻었다.2,000 ml of toluene in 344.3 g (1 mole) of ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate and 296.4 g (2 mole) of triethylolsoformate The solution dissolved in was heated to 110 ° C. and stirred for 24 hours. After the reaction was completed, 1,000 ml of water was added thereto, and vigorously stirred, the toluene layer was separated, and washed with the same amount of water again. The reaction mixture was dried over magnesium sulfate, distilled under reduced pressure to remove the solvent, and 323.5 g (99%) of ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) ] Benzoyl acrylate was obtained.
IR: υmax(cm-1): 1692, 1666, 1624, 1593IR: υ max (cm -1 ): 1692, 1666, 1624, 1593
H1NMR(CDCl3, 300MHz) (ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):
0.92 및 1.26(6H, 각각 t, -CO2CH2CH3, 및 CHOCH2CH3),0.92 and 1.26 (6H, t, —CO 2 CH 2 CH 3 , and CHOCH 2 CH 3, respectively ),
2.41(3H, s, -NCH3), 2.28~2.43(4H, m, 피페라진 H),2.41 (3H, s, -NCH 3 ), 2.28-2.43 (4H, m, piperazine H),
3.52~3.70(4H, m, 피페라진 H),3.52-3.70 (4H, m, piperazine H),
4.15 및 4.49(4H, 각각 q, -CO2CH2CH3, 및 =CHOCH2CH3),4.15 and 4.49 (4H, q, -CO 2 CH 2 CH 3 , and = CHOCH 2 CH 3, respectively ),
6.74~6.85(1H, m, 방향성 H),6.74-6.85 (1H, m, Directional H),
8.21 및 8.32(1H, 각각 d, =CHO-)8.21 and 8.32 (1H, d, = CHO- respectively)
실시예 5: 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)] 벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트의 제조Example 5: Ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropy-2-ylamino Production of acrylate
344.3g(1mole)의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트와 296.4g(2mole)의 트리에틸올소포르메이트를 2,000ml의 톨루엔에 녹인 용액을 110℃까지 가열하여 24시간 동안 교반하고 톨루엔을 감압증류하여 제거시킨 후 2,000ml의 에탄올에 다시 녹였다. 여기에 112.7g(1.5mole)의 (S)-(+)-2-아미노-1-프로판올을 서서히 적가한 다음 상온에서 3시간 격렬하게 교반시켰다. 반응이 완결되면 감압증류하여 에탄올을 제거시켜 420.8g(98%)의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트를 얻었다.344.3 g (1 mole) of ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate and 296.4 g (2 mole) of triethylolsoformate in 2,000 ml of toluene The dissolved solution was heated to 110 ° C., stirred for 24 hours, toluene was distilled off under reduced pressure, and then dissolved in 2,000 ml of ethanol. 112.7 g (1.5 mole) of (S)-(+)-2-amino-1-propanol was slowly added dropwise thereto, followed by vigorous stirring at room temperature for 3 hours. After completion of the reaction, the reaction mixture was distilled under reduced pressure to remove ethanol, and 420.8 g (98%) of ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 ( S)-(1-hydroxypropy-2-ylamino) acrylate was obtained.
IR: υmax(cm-1) : 1,681, 1,668, 1,625IR: υ max (cm -1 ): 1,681, 1,668, 1,625
H1NMR (CDCl3, 300MHz)(ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):
0.98 and 1.09 (3H, 각각 t, -OCH2CH3), 1.35 (3H, d, -NHCHCH3),0.98 and 1.09 (3H, t, -OCH 2 CH 3 ), 1.35 (3H, d, -NHCHCH 3 ),
1.80∼2.20 (1H, br, -OH), 2.35 (3H, s, =NCH3),1.80-2.20 (1H, br, -OH), 2.35 (3H, s, = NCH 3 ),
2.30∼2.65 (4H, m, 피페라진 H), 3.20∼3.50 (4H, m, 피페라진 H),2.30 to 2.65 (4H, m, piperazine H), 3.20 to 3.50 (4H, m, piperazine H),
3.40∼3.60 (3H, m, =NCHCH2O-), 4.03 and 4.07 (2H, 각각 q, -OCH2CH3),3.40 to 3.60 (3H, m, = NCHCH 2 O-), 4.03 and 4.07 (2H, q and -OCH 2 CH 3 ),
6.80∼6.90 (1H, m, 방향성 H), 8.15 and 8.20 (1H, 각각 d, =CHN=),6.80 to 6.70 (1H, m, aromatic H), 8.15 and 8.20 (1H, d, = CHN =),
9.20∼9.70 and 10.50∼11.00 (1H, 각각 br, =NH)9.20-9.70 and 10.50-11.00 (1H, respectively br, = NH)
[α]D= -68.3° (c=0.12, CHCl3)[α] D = -68.3 ° (c = 0.12, CHCl 3 )
본 발명의 제조방법으로 제조된 상기 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트는 항균제로 유용한 약제인 레보플록사신의 제조시 중간체로 유용하게 사용할 수 있다.Ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropy) prepared by the preparation method of the present invention. 2-Nylamino) acrylate can be usefully used as an intermediate in the preparation of levofloxacin, a drug useful as an antibacterial agent.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-1999-0034793A KR100494881B1 (en) | 1999-08-21 | 1999-08-21 | Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)]benzoyl-3(S)-(1-hydroxyprop-2-ylamino)acrylate and a process for preparing thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-1999-0034793A KR100494881B1 (en) | 1999-08-21 | 1999-08-21 | Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)]benzoyl-3(S)-(1-hydroxyprop-2-ylamino)acrylate and a process for preparing thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010018722A true KR20010018722A (en) | 2001-03-15 |
KR100494881B1 KR100494881B1 (en) | 2005-06-14 |
Family
ID=19608177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-1999-0034793A KR100494881B1 (en) | 1999-08-21 | 1999-08-21 | Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)]benzoyl-3(S)-(1-hydroxyprop-2-ylamino)acrylate and a process for preparing thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100494881B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170025811A (en) | 2015-08-31 | 2017-03-08 | 동양알코아 주식회사 | aluminium grating |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62215591A (en) * | 1986-03-14 | 1987-09-22 | Dainippon Pharmaceut Co Ltd | Production of pyridobenzoxazine derivative and intermediate therefor |
KR920002192B1 (en) * | 1988-06-02 | 1992-03-19 | 죠오 호꾸 고교 가부시기가이샤 | Manipulaten for executing building works |
KR920012087A (en) * | 1990-12-27 | 1992-07-25 | 하기주 | Method for preparing benzoxazine derivatives |
KR960009997B1 (en) * | 1992-08-25 | 1996-07-25 | 금성일렉트론 주식회사 | Semiconductor memory cell and manufacturing method thereof |
KR100248370B1 (en) * | 1997-12-04 | 2000-03-15 | 이종배 | Preparation of intermediate of (-)-3(s)-methylpyrido benzoxizine derivative |
-
1999
- 1999-08-21 KR KR10-1999-0034793A patent/KR100494881B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170025811A (en) | 2015-08-31 | 2017-03-08 | 동양알코아 주식회사 | aluminium grating |
Also Published As
Publication number | Publication date |
---|---|
KR100494881B1 (en) | 2005-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR840002141B1 (en) | Process for preparing benzoxazine derivatives | |
KR950011396B1 (en) | Intermediate compound for preparing 4-oxoquinoline-3-carboxylic acid derivatives | |
US4777253A (en) | Process for preparation of racemate and optically active ofloxacin and related derivatives | |
EP3380464A1 (en) | Iminotetrahydropyrimidinone derivatives as plasmepsin v inhibitors | |
FR2598709A1 (en) | QUINOLINE-CARBOXYLIC ACID DERIVATIVES | |
US5521310A (en) | Process to obtain benzoxazines to be used for the synthesis of ofloxazine, levofloxazine and derivatives | |
KR100309871B1 (en) | Process for Preparing (-)Pyridobenzoxazine Carboxylic Acid Derivatives | |
JPH0692371B2 (en) | Novel heterocyclic derivative, method for producing the same, and method for producing a medicine containing these and particularly useful as an aldose reductase inhibitor | |
KR100251522B1 (en) | Pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group and pharmaceutically acceptable salts thereof | |
KR20010018722A (en) | Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate and a process for preparing thereof | |
US4826985A (en) | Intermediates for preparation of racemate and optically active ofloxacin and related derivatives | |
KR100248370B1 (en) | Preparation of intermediate of (-)-3(s)-methylpyrido benzoxizine derivative | |
KR960004825B1 (en) | Novel quinolone compounds and method of preparing them (ñ�) | |
EP0675880B1 (en) | Quinoline disulfides as intermediates | |
KR100355756B1 (en) | Method for manufacturing a S-ofloxacin | |
KR100334462B1 (en) | A process for producing ethyl 2-(2,3,4,5-tetrafluorobenzoyl)-3(S)-(1-hydroxyprop-2-ylamino)acrylate | |
KR100494880B1 (en) | A process for preparing Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate | |
JPH04270272A (en) | Production of aminoalkylmorpholine derivative | |
KR100494882B1 (en) | A process for preparing (-)-9-Fluoro-2,3-dihydro-3(S)-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid | |
KR100310786B1 (en) | Process for Preparing Optically Active Quinolone Carboxylic Acid Derivatives | |
HU214955B (en) | Process for producing fluoro-quinoline carboxylic-3-acid derivatives | |
KR100440192B1 (en) | Method of preparing optical active quinolonecarboxylic acid derivatives | |
KR970000950B1 (en) | Benzoheterocyclic compounds and their preparing method | |
HU204256B (en) | Process for producing quinoline-2,5-dions and pharmaceutical compositions containing them | |
KR20010019386A (en) | A process for preparing (-)-9,10-Difluoro-2,3-dihydro-3(S)-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20101224 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20111228 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150106 Year of fee payment: 13 |